STAT3 and COVID-19: Since STAT3 is a pro-inflammatory mediator, STAT3 inhibition by SBT-100 may also decrease some of the inflammatory complications associated with checkpoint inhibitor therapy such as pneumonitis [34] and severe COVID-19 pathology.